testosterone cypionate 200 MG/ML Injectable Solution

What the CMS Formulary Data Shows for testosterone cypionate 200 MG/ML Injectable Solution

Per the CMS 2026 Part D formulary file, testosterone cypionate 200 MG/ML Injectable Solution (RxNorm concept RXCUI 835840, generic name testosterone cypionate) appears on 312 distinct formulary files spanning 4,997 Medicare Part D plan offerings - 98.9% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.1.

Real-world access to testosterone cypionate 200 MG/ML Injectable Solution depends on utilization management as much as tier placement: 67.6% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 242,810 Part D beneficiaries filled testosterone cypionate 200 MG/ML Injectable Solution in 2023, with total plan-and-beneficiary spending of $37,966,482 and an average per-beneficiary annual cost of $156.36. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry testosterone cypionate 200 MG/ML Injectable Solution today.